UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 860

Sortiert nach

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Journal of hematology and oncology, 2022-01, Vol.15 (1), p.4-4, Article 4

2022

Volltextzugriff (PDF)

Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1256-1265

2001

Volltextzugriff (PDF)

Pocket ultrasound device, PM & rehabilitation physician's stethoscope

Rehabilitacion, 2023-04, Vol.57 (2), p.100746

2023

Volltextzugriff (PDF)

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy

Annals of oncology, 2021-10, Vol.32 (10), p.1295-1297

2021

Volltextzugriff (PDF)

Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin

Anti-cancer drugs, 2003-08, Vol.14 (7), p.487-502

2003

Volltextzugriff (PDF)

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

Annals of oncology, 1999-10, Vol.10 (10), p.1233-1240

1999

Volltextzugriff (PDF)

PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors

Annals of oncology, 2018-10, Vol.29 Suppl 8, p.viii143

2018

Volltextzugriff (PDF)

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry

Journal of mass spectrometry., 2002-09, Vol.37 (9), p.992-1000

2002

Volltextzugriff (PDF)

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study

Clinical cancer research, 2000-12, Vol.6 (12), p.4725-4732

2000

Volltextzugriff (PDF)

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Sarcoma, 2006, Vol.2006, p.56282-11

2006

Volltextzugriff (PDF)

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Journal of mass spectrometry., 1998-11, Vol.33 (11), p.1134-1140

1998

Volltextzugriff (PDF)

Pharmaceutical development of anticancer agents derived from marine sources

Anti-cancer drugs, 2000-11, Vol.11 (10), p.793-811

2000

Volltextzugriff (PDF)

Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity

Toxicology in vitro, 2001-08, Vol.15 (4), p.571-577

2001

Volltextzugriff (PDF)

A clinical armamentarium of marine-derived anti-cancer compounds

Anti-cancer drugs, 2002-05, Vol.13 Suppl 1, p.S15-S19

Jimeno, José M

2002

Volltextzugriff (PDF)

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F

Drug development and industrial pharmacy, 2001-01, Vol.27 (8), p.767-780

2001

Volltextzugriff (PDF)

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion

Cancer chemotherapy and pharmacology, 2001-12, Vol.48 (6), p.459-466

2001

Volltextzugriff (PDF)

437PPT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine

PDA journal of pharmaceutical science and technology, 2000-05, Vol.54 (3), p.193

2000

Volltextzugriff (PDF)

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol

PDA journal of pharmaceutical science and technology, 2001-07, Vol.55 (4), p.223

2001

Volltextzugriff (PDF)

Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate

Experimental hematology, 1993-10, Vol.21 (11), p.1413

1993

Volltextzugriff (PDF)

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F

Anti-cancer drugs, 2001-08, Vol.12 (7), p.575-582

2001

Volltextzugriff (PDF)

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

Anti-cancer drugs, 2001-09, Vol.12 (8), p.653-666

2001

Volltextzugriff (PDF)

Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo‐ionspray tandem mass spectrometry

British journal of clinical pharmacology, 2002-05, Vol.53 (5), p.543P-543P

2002

Volltextzugriff (PDF)

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

Clinical cancer research, 2005-03, Vol.11 (5), p.1854-1862

2005

Volltextzugriff (PDF)

1 – 25 von 860

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(671)
Mit Volltextzugriff
(679)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Plitidepsin as a successful rescue treatment for prolonged viral SARS-CoV-2 replication in a patient with previous anti-CD20 monoclonal antibody-mediated B cell depletion and chronic lymphocytic leukemia

Phase I and Pharmacokinetic Study of Ecteinascidin-743, a New Marine Compound, Administered as a 24-hour Continuous Infusion in Patients With Solid Tumors

Pocket ultrasound device, PM & rehabilitation physician's stethoscope

Plitidepsin for the management of a cancer patient infected with SARS-CoV-2 while receiving chemotherapy

Yondelis® (trabectedin, ET-743): the development of an anticancer agent of marine origin

High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer

PT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors

Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry

Pharmacokinetics and Pharmacodynamics of the Novel Marine-derived Anticancer Agent Ecteinascidin 743 in a Phase I Dose-finding Study

Ecteinascidin-743: Evidence of Activity in Advanced, Pretreated Soft Tissue and Bone Sarcoma Patients

Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry

Pharmaceutical development of anticancer agents derived from marine sources

Evaluation of the use of in vitro methodologies as tools for screening new compounds for potential in vivo toxicity

A clinical armamentarium of marine-derived anti-cancer compounds

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F

Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19

A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion

437PPT-112: A well-tolerated novel immunogenic cell death (ICD) inducer with activity in advanced solid tumors

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol

Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate

Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F

Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man

Bioanalysis of the novel peptide anticancer drug kahalalide F in human plasma by h.p.l.c. under basic conditions coupled with positive turbo‐ionspray tandem mass spectrometry

Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer

Suchergebnisse filtern